Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

hese efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month-formulations of triptorelin.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About Ipsen

Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patien
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
(Date:3/3/2015)... SAN CARLOS, Calif. , March 3, 2015 /PRNewswire/ ... with expertise in drug-disease modeling and simulation research, today ... during the 2015 American Society for Clinical Pharmacology and ... March 3-7 2015.   Logo - ... and Rosa will present a poster describing a ...
(Date:3/3/2015)... 3, 2015 Kindred Biosciences, Inc. (NASDAQ: ... the lives of pets, announced today that it will release ... 12, 2015 after the market close. The Company will host ... Interested parties may access the call by ... internationally, and using conference ID 98449349.  The ...
(Date:3/3/2015)... March 03, 2015 Genedata, a ... discovery and life science research, today announced that ... enterprise platform for use at Pfizer biopharma research ... Genedata is supporting Pfizer’s global deployment and roll ... Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... Jlich/Aachen, 3 May 2011 - Optical data carriers such ... of so-called "phase change materials". In the future, these ... energy-saving main memories. A prerequisite for this is a ... low thermal conductivity even in the crystalline state. This ...
... Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial ... Total revenue increased to $49.8 million in the first ... of 2010.  Product revenue was $49.5 million in the first quarter ... in the first quarter of 2010. Net loss ...
... 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... China-based biotechnology company focused on researching, developing, manufacturing ... will release its first quarter 2011 unaudited financial ... Wednesday, May 11, 2011 at 8:00pm (US Eastern ...
Cached Biology Technology:Nature of bonding determines thermal conductivity 2Nature of bonding determines thermal conductivity 3Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 2Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 3Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 4Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 5Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 6Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 7Genomic Health Announces First Quarter 2011 Financial Results and Business Progress 83SBio Inc. Schedules Unaudited First Quarter 2011 Results 2
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... "ear" for flying in the dark because of a ... physical environment by listening to echoes. But an Ohio ... it, too. , John Zook's studies of bat flight ... maintain altitude and catch insects in midair. His preliminary ...
... has found that the numbers of men ?especially students ... 2000, almost certainly due to growing awareness that changes ... anonymity. , The fall in applications, leading to a ... from the Newcastle Fertility Centre at LIFE to call ...
... MIT and one from the University of California at ... issue of Science dedicated to the brain that the ... brain development are dead. , The cerebral cortex is ... distinctly separate areas that process particular aspects of sensation, ...
Cached Biology News:Bats use touch receptors on wings to fly, catch prey, study finds 2Bats use touch receptors on wings to fly, catch prey, study finds 3UK sperm donor crisis 2UK sperm donor crisis 3MIT researcher presents new view of how the cortex forms 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Mouse anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... assay dependent dilution. ICC: Use at an assay ... 5 - 10 ug/ml, this concentration is determined ... molecular weight: 40 kDa. Not tested in other ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: